Summary: Although thrombolytic therapy has been a major advance in the treatment of acute ST- segment elevation myocardial infarction (MI), new thrombolytic agents have been unable to improve early reperfusion. Because aspirin has been shown to be a very effective adjunctive agent in patients with acute MI, it has been hypothesized that the use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors combined with thrombolytic agents would lead to more effective platelet inhibition and improved angiographic and clinical efficacy. Emerging experimental and clinical data, including the Thrombolysis in Myocardial Infarction (TIMI)-14 trial, suggest that combining GP IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk. Thus, given the strong clinical and physiologic rationale, clinical investigation in patients with acute ST-segment elevation MI is currently focused on combining GP IIb/IIIa receptor inhibitors with reduceddose fibrinolytic agents in acute MI. Key words: thrombolysis, fibrinolysis, glycoprotein IIb/IIIa, acute coronary syndrome, combination
|
7
|
per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet
– Italiano
|
|
6
|
International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet
– ISIS-2
|
|
5
|
Molecular bases of the acute coronary syndromes. Circulation
– Libby
- 1995
|
|
4
|
Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes
– Fuster
- 1992
|
|
3
|
Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis
– Roux, Christeller, et al.
- 1992
|
|
3
|
Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin �3 blockade with percutaneous coronary intervention. J Am Med Assoc 1997;
– EJ, JJ, et al.
|
|
3
|
Hirudin in acute myocardial infarction: safety report from the Thrombolysis and
– EM
|
|
2
|
Braunwald E: GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49:1–8
– CP
|
|
2
|
Higashino Y, Fujii K, Masuyama T, Kitabatake A: Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699–1705
– Ito, Tomooka, et al.
|
|
2
|
Topol EJ: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
– AM, RM, et al.
- 1997
|
|
2
|
Gawaz M, Kastrati A, Schomig A: Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695–2701
– Neumann, Blasini, et al.
|
|
2
|
Byzova TV, Plow EF: Platelet GP IIb/IIIa blockers. Lancet 1999;353:227–231
– EJ
|
|
2
|
Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy
– Kleiman, EM, et al.
|
|
2
|
SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG
– EM, NS, et al.
|
|
2
|
Meeting highlights: 47th Annual Scientific Sessions of the American College of Cardiology. Circulation 1998;97: 2377–2381
– JJ
- 1998
|
|
2
|
Hirudin in acute myocardial infarction: Thrombolysis and Thrombin
– EM
|
|
1
|
Topol EJ, Candela R, Abbottsmith C
– EM, RM
- 1990
|
|
1
|
CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E: TNKtissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of th
– CP, CM, et al.
|
|
1
|
LG, Feldman RL, Seals AA, Weaver WD: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients wit
– Bode, RW, et al.
|
|
1
|
Perritt RL, Poole WK, Braunwald E: Prospective validation of a composite end point in thrombolytic Clin
– CP, PJ, et al.
- 1999
|
|
1
|
ME: Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1988;97:26–33
– Belle, Lablanche, et al.
|
|
1
|
PK, Fuster V: Coronary plaque disruption. Circulation 1995;92:657–671
– Falk, Shah
|
|
1
|
MJ: The composition of coronary-artery plaques
– Davies
- 1997
|
|
1
|
Ziskand AA, Leinbach RC, Fallon JT, Collen D: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219–225
– IK, HK
|
|
1
|
Houtte E, Declerck PJ, Collen D: Streptokinaseinduced platelet aggregation: Prevalence and mechanism. Circulation 1991;84:84–91
– DE, Van
|
|
1
|
BS: Platelets and thrombolytic therapy
– Coller
- 1990
|
|
1
|
Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
– JI
- 1990
|
|
1
|
Powers ER: Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient activity. Blood 1988;72:616–620
– Owen, KD, et al.
|
|
1
|
Carpo C, Ohman E, Topol E: Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment
– Gurbel, Serebruany, et al.
|
|
1
|
or both to treat unstable angina
– Théroux, Ouimet, et al.
- 1988
|
|
1
|
CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa
– BS, EI, et al.
|
|
1
|
HC, Coller BS: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.” J Clin Invest 19
– JC, Beguin, et al.
|
|
1
|
HF, Topol EJ: Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
– Lefkovits, RJ, et al.
- 1996
|
|
1
|
EJ: Randomized, placebo-controlled trial of platelet IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734–741
– SJ, LA, et al.
|
|
1
|
RC, Ziskind AA, Collen DS: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988;77:670–
– HK, BS, et al.
|
|
1
|
JT, Collen D: Lysis of plasminogen activator-resisC. P. Cannon: GP IIb/IIIa inhibitors plus thrombolysis IV-43 tant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP I
– Yasuda, HK, et al.
|
|
1
|
McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R
– EM, RP, et al.
|
|
1
|
Presented at the 48th Annual Scientific
– SPEED
- 1999
|
|
1
|
de Werf FJ, Braunwald E: Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage
– RP, CP, et al.
|
|
1
|
Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Chow F, Fox NL, Braunwald E: Safety assessment of single bolus administration of TNKtPA in acute myocardial infarction: The ASSENT-I trial. Am Heart J
– Werf
- 1999
|
